This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Click here for Prevenar 13® (pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Prevenar 13 Private

Prevenar 13 Adult Private Vaccination

Prevenar 13 is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in adults ≥ 18 years of age and the elderly.1

  • Each year, up to 1 in every 100 UK adults develop pneumonia. Pneumonia can be caused by viruses, bacteria and fungi. Streptococcus pneumoniae is the most common bacterial cause.2,3
  • Offers adults the proven, lasting protection of Prevenar 13 all year round.4*​​​​​​​
  • People can choose to pay privately for a vaccination, to help protect themselves with Prevenar 13.

* vs placebo.4 Data from a randomised, placebo-controlled, double-blind trial demonstrated the efficacy of Prevenar 13 vs placebo in the prevention of a first episode of confirmed vaccine-type community-acquired pneumococcal pneumonia in adults aged > 65 years of age.4 Post-hoc analysis showed that the efficacy of Prevenar 13 vs placebo persisted throughout the 4-year trial.4

Risk Groups

Pneumococcal pneumonia can strike people of any age.3 However, many factors put adults at increased risk of pneumococcal infections, including pneumococcal pneumonia, making them potential candidates for vaccination.3,5-11

​​​​​​​
  • Aged>45 years: The risk of contracting pneumococcal pneumonia increases from the age of 45 onwards.5-7 
  • Smoking: Smokers are 4.4 times* more likely to develop pneumonia than someone who has never smoked.11 
  • Exposure to lots of people in close contact: Examples of this include the Hajj and Umrah pilgrimages. A 2.7 fold increase in nasal carriage rate of Streptococcus pneumoniae was reported in pilgrims returning from Hajj in 2012.10
  • Travelling: Many of the world’s most popular tourist destinations13, including South Asia and parts of Africa are also home to higher levels of pneumococcal infections.12 Some countries, like China and Thailand, do not routinely immunise against pneumococcal disease.14 Others, like India, have only started vaccinating recently.14
  • Chronic conditions including asthma, respiratory disease, heart disease, diabetes, liver disease and kidney disease.11
  • Those who have already had pneumonia or have flu: People who have had pneumonia in the past are twice as likely to get pneumonia again compared with people who have never had pneumonia. Those who have a flu infection are up to 100 times more likely to develop pneumonia.15,16

So, there are a lot of occasions where you can help protect your patients with Prevenar 13 vaccination.12

**Risk data above is for people aged 50-64. People aged 18-49 had lower ratios and ≥ 65 had higher ratios.

E Learning Modules

Access E-learning modules for our Vaccine brands

E learning modules

Materials to support the delivery of your private vaccination service

  1. A framework for setting up a private vaccination service
  2. Prevenar 13 Quick Reference guide

1) Private vaccination service

2) Prevenar 13 Quick
​​​​​​​Reference Guide
​​​​​​​References
  1. Prevenar 13® Summary of Product characteristics. November 2020.
  2. ​​​​​​​Lim W, Baudouin S, George R et al. BTS guidelines for the management of community-acquired pneumonia in adults: update 2009. Thorax 2009; 64 (Suppl 3): iii1–iii55.
  3. NHS UK. Pneumonia. Available at https://www.nhs.uk/conditions/pneumonia/. Last accessed March 2021​​​​​​​.
  4. Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114-25.
  5. Miller E,  Andrews NJ, Waight PA, et al. Herd immunity and serotype replacement 4 years after seven valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. LancetInfectDis 2011;11:760-768.
  6. Hospital Episodes statistics data accessed March 2018. Ages >16, ICD-10 codes J12-J18, England only data.
  7. Pick H, Daniel P, Rodrigo C, et al. pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013-18. Thorax Epub 2019;0:1-12.
  8. Public Health England. The Green Book, Chapter 25: Pneumococcal. Available at: https://www.gov.uk/government/publications/pneumococcal-the-green-book-chapter-25. Last accessed March 2021.
  9. Public Health England. Guidelines for the public health management of clusters of severe pneumococcal disease in closed settings. Available at: https://www.gov.uk/government/publications/managing-clusters-of-pneumococcal-disease-in-closed-settings. Last accessed March 2021.
  10. Benkouiten S, Gautret P, Belhouchat K, et al. Acquisition of Streptococcus pneumoniae carriage in pilgrims during the 2012 Hajj. Clin Infect Dis. 2014;58(4):e106-9.
  11. Shea KM, Edelsburg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open forum Infect Dis. 2014;1-9.
  12. Ferreira D, Jambo KC, Gordon SB. Experimental human pneumococcal carriage models for vaccine research. Trends Microbiol. 2011;19(9):464-70.
  13. World Tourism Organisation. International tourism highlights 2019. Available at: https://www.e-unwto.org/doi/pdf/10.18111/9789284421152. Last accessed March 2021.
  14. International Vaccine Access Centre (IVAC), View-hub. Available at: https://www.view-hub.org. Last accessed March 2021.
  15. Almirall J, Bolíbar I, Serra-Prat M, et al. New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J. 2008 Jun;31(6):1274-84.
  16. Shrestha S, Foxman B, Berus J, et al. The role of influenza in the epidemiology of pneumonia. Sci Rep. 2015 Oct 21;5:15314.
PP-PNA-GBR-0444. March 2021

Patient materials

Order your patient materials to support your services

Order patient materials

A website to provide information on pneumonia specifically for the general public

View Site

Find out how the Pfizer Vaccines team can support your private vaccination service

Contact our Pfizer Vaccines team
​​​​​​​

Call

Email

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No